Tyrosine kinase inhibitors (TKIs) are used in clinic to treat chronic myeloid leukemia (CML). TKIs should be taken for life but some patients stop treatment due to antileukemic deep molecular response (DMR). Some TKIs may also induce a potent immune response against CMV and our group described an inhibition of HIV infection in vitro and in vivo. Many mechanisms define TKIs activity against HIV: 1) cytostatic effect and inhibition of cytokine-dependent proliferation, possibly affecting reservoir establishment and replenishment 2) maintenance of SAMHD1antiviral activity 3) sustained cytotoxic activity to control the growth of cancerous cells even after withdrawal. Objectives: 1) to analyze cytotoxic effect in CML patient cell populations during TKI treatment and after withdrawal; 2) to determine the susceptibility to HIV infection of CD4 T cells from CML patients off TKI treatment.
PBMCs from CML patients on TKI treatment for avg. 3.8±0.5y (dasatinib n=20; imatinib n=11; nilotinib n=9; bosutinib n=5; ponatinib n=1), CML patients off TKI treatment for avg. 2.3±0.3y due to DMR (last TKI: dasatinib=4; imatinib=7; nilotinib=6) and healthy donors (n=30) were analyzed by flow cytometry. IFNg synthesis was analyzed by flow cytometry and proviral integration by Alu-qPCR.
1) Active NK cells CD56+CD16+CD107a+ were increased >6-fold in patients on treatment with all TKIs except imatinib, compared to control. This population remained >5-fold enhanced after withdrawal. 2) CD8±TCRgd+ lymphocytes were increased >2-fold in patients on treatment and remained >3-fold greater in patients off treatment. 3) Synthesis of IFNg in response to in vitro CMV pp65 peptide was increased >2-fold in CD8+CD69+ T cells from patients off treatment. However, no CD8 reactivation was detected in patients on treatment probably due to the potent cytostatic effect of TKIs. 4) In vitro treatment with TKI dasatinib and IL-15 increased >2.5-fold the IFNg secretion from NK cells. 5) PBMCs from patients off treatment showed <12-fold proviral integration after in vitro infection
TKIs induce mechanisms with antiviral activity that may be used against HIV infection. Populations of active NK cells and IFNg-secreting CD8 cells may persist in CML patients even after treatment withdrawal, as well as CD4 cells resistant to HIV infection. These results suggest a possible transient use of TKIs in HIV-infected patients to establish a persistent antiviral activity